Bausch Health Companies Inc. (TSE:BHC - Free Report) - Research analysts at Zacks Research decreased their Q2 2025 earnings estimates for shares of Bausch Health Companies in a research note issued on Monday, June 23rd. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $1.36 for the quarter, down from their prior forecast of $1.37. The consensus estimate for Bausch Health Companies' current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies' Q3 2025 earnings at $1.46 EPS, FY2025 earnings at $5.27 EPS, Q1 2026 earnings at $1.21 EPS, Q2 2026 earnings at $1.35 EPS, Q3 2026 earnings at $1.57 EPS, Q4 2026 earnings at $1.54 EPS, FY2026 earnings at $5.67 EPS, Q1 2027 earnings at $1.51 EPS and FY2027 earnings at $6.71 EPS.
Bausch Health Companies Trading Up 1.0%
TSE:BHC traded up C$0.09 during trading hours on Thursday, reaching C$8.83. The company's stock had a trading volume of 672,617 shares, compared to its average volume of 366,877. The firm has a market capitalization of C$2.30 billion, a price-to-earnings ratio of -12.92, a PEG ratio of 0.21 and a beta of 0.77. The firm has a 50-day simple moving average of C$7.08 and a 200-day simple moving average of C$8.92. Bausch Health Companies has a 1 year low of C$5.45 and a 1 year high of C$13.74. The company has a debt-to-equity ratio of -1,831.94, a quick ratio of 0.58 and a current ratio of 1.19.
Insider Buying and Selling
In other news, Director John Paulson purchased 754,134 shares of the business's stock in a transaction on Tuesday, June 10th. The shares were acquired at an average price of C$6.87 per share, with a total value of C$5,179,392.31. Insiders have acquired a total of 3,553,401 shares of company stock worth $27,087,675 in the last 90 days. 11.28% of the stock is owned by company insiders.
About Bausch Health Companies
(
Get Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
Further Reading
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
